Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | EGFR | P00533 | 4/20 | 0.50 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.50 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.50 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1722127 | 1.00 | KDM4E (0.55) | KDM4ELMNAALDH1A1EGFRCISD1 | |
| SCHEMBL1722125 | 1.00 | KDM4E (0.55) | KDM4ELMNAALDH1A1EGFRCISD1 | |
| SCHEMBL3028840 | 0.85 | LMNA (0.49) | KDM4ELMNAALDH1A1EGFRCISD1 | |
| SCHEMBL3028841 | 0.85 | LMNA (0.49) | KDM4ELMNAALDH1A1EGFRCISD1 | |
| SCHEMBL14689450 | 0.84 | EGFR (0.49) | KDM4ELMNAALDH1A1EGFRCISD1 | |
| SCHEMBL2459356 | 0.84 | EGFR (0.49) | KDM4ELMNAALDH1A1EGFRCISD1 | |
| SCHEMBL14689684 | 0.82 | EGFR (0.46) | KDM4EALDH1A1EGFRCISD1SLC16A3 | |
| SCHEMBL2458555 | 0.82 | EGFR (0.46) | KDM4EALDH1A1EGFRCISD1SLC16A3 | |
| SCHEMBL10794933 | 0.81 | KDM4E (0.54) | KDM4ELMNAALDH1A1EGFRCISD1 | |
| SCHEMBL10794927 | 0.81 | KDM4E (0.54) | KDM4ELMNAALDH1A1EGFRCISD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8729274-B2 | Tricyclic heterocyclic derivatives | MERCK SHARP & DOHME B.V. (NL) | 2014-05-20 | — | — | US | disclosed |
| US-8729274-B2 | Tricyclic heterocyclic derivatives | MERCK SHARP & DOHME B.V. (NL) | 2014-05-20 | — | — | US | disclosed |
| US-20120232122-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES | MERCK SHARP & DOHME B.V. (NL) | 2012-09-13 | — | — | US | disclosed |
| US-20120232122-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES | MERCK SHARP & DOHME B.V. (NL) | 2012-09-13 | — | — | US | disclosed |
| WO-2010103001-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES | N.V. ORGANON (NL) | 2010-09-16 | — | — | WO | disclosed |
| EP-1620102-B1 | 3-(1-NAPHTHYL)-2-CYANOPROPANOIC ACID DERIVATIVES AS ESTROGEN RECEPTOR LIGANDS | WYETH CORP (US) | 2008-12-24 | — | — | EP | disclosed |
| US-20070299105-A1 | 2-Cyanopropanoic Acid Amide and Ester Derivatives and Methods of Their Use | WYETH (US) | 2007-12-27 | — | — | US | disclosed |
| EP-1620102-A2 | 3-(1-NAPHTHYL)-2-CYANOPROPANOIC ACID DERIVATIVES AS ESTROGEN RECEPTOR LIGANDS | Wyeth (US) | 2006-02-01 | — | — | EP | disclosed |
| US-20050256132-A1 | Use of ER selective NF-kB inhibitors for the treatment of sepsis | WYETH (US) | 2005-11-17 | — | — | US | disclosed |
| US-20050004164-A1 | 2-Cyanopropanoic acid amide and ester derivatives and methods of their use | WYETH | 2005-01-06 | — | — | US | disclosed |
| WO-2004099150-A2 | 3-(1-NAPHTHYL)-2-CYANOPROPANOIC ACID DERIVATIVES AS ESTROGEN RECEPTOR LIGANDS | WYETH (US) | 2004-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256132-A1 | Use of ER selective NF-kB inhibitors for the treatment of sepsis | NFKBIA, IKBKB, NFKB2 | KDM4E 1711/4885LMNA 3473/4885ALDH1A1 4483/4885 |
| US-20070299105-A1 | 2-Cyanopropanoic Acid Amide and Ester Derivatives and Methods of Their Use | HCAR2, PCCA, MCCC2 | KDM4E 2551/4885LMNA 2633/4885ALDH1A1 1159/4885 |
| US-20050004164-A1 | 2-Cyanopropanoic acid amide and ester derivatives and methods of their use | HCAR2, PCCA, MCCC2 | KDM4E 2836/4885LMNA 2736/4885ALDH1A1 1172/4885 |
| US-20120232122-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES | TPH1, HTR3C, TPH2 | KDM4E 1570/4885LMNA 2618/4885ALDH1A1 448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.